BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is developing therapies to destroy cancer

Join the BriaCell Team!BriaCell Therapeutics is expanding, and we’re looking for enthusiastic, driven professionals read...
03/20/2026

Join the BriaCell Team!

BriaCell Therapeutics is expanding, and we’re looking for enthusiastic, driven professionals ready to make a difference in cancer treatment. If you’re passionate about biotech innovation and thrive in a collaborative environment, we want to hear from you!

Explore our current opportunities here: https://bit.ly/478ecPX

03/19/2026

BriaCell President and CEO, Dr. William V. Williams, shares his thoughts on the Company’s four poster presentations at the upcoming 2026 American Association for Cancer Research (AACR) Annual Meeting taking place from April 17th – 22nd. Discover more: https://bit.ly/4uAQJkl

BriaCell is hiring!Briacell Therapeutics is expanding our team and looking for passionate, driven individuals to join us...
03/18/2026

BriaCell is hiring!

Briacell Therapeutics is expanding our team and looking for passionate, driven individuals to join us in advancing innovative cancer treatments. If you’re ready to make a meaningful impact in biotech and work alongside a dedicated team, we’d love to hear from you.

Explore our open roles and take the next step in your career today. https://briacell.com/careers/

03/18/2026

BriaCell (Nasdaq: BCTX, BCTXL) (TSX: BCT) will present four posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22 at the San Diego Convention Center in San Diego, California.

The presentations will include one poster featuring data from BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor (ClinicalTrials.gov identifier: NCT06072612), two posters highlighting further analyses of Phase 2 data, and one poster presenting preclinical data related to Bria-OTS+, BriaCell’s next-generation personalized off-the-shelf immunotherapy for cancer. Find details: https://bit.ly/4uAQJkl

BriaCell is Hiring: Scientist / Senior Scientist – Quality Control (Philadelphia, PA)Join BriaCell and contribute to the...
03/17/2026

BriaCell is Hiring: Scientist / Senior Scientist – Quality Control (Philadelphia, PA)

Join BriaCell and contribute to the development, qualification, and ex*****on of analytical assays used to characterize cell-based immunotherapies and support research, development, and manufacturing programs!

📍 Location: Philadelphia, PA
💼 Department: Research & Development
✅ Must be authorized to work in the US under any employer

Apply now and see all details:
https://briacell.com/careers/

03/13/2026

ICYMI: BriaCell announced that four abstracts have been accepted for poster presentation at the AACR Annual Meeting, taking place April 17th - 22nd.

The accepted abstracts highlight research related to BriaCell’s cellular immunotherapy platform, including the Company’s ongoing pivotal Phase 3 study of Bria-IMT™ in combination with an immune checkpoint inhibitor and research supporting Bria-OTS+™, BriaCell’s next-generation personalized off-the-shelf immunotherapy program.

Learn more: https://bit.ly/4uqVJZ4

03/10/2026

BriaCell (Nasdaq: BCTX, BCTXL) (TSX: BCT) announced that four abstracts have been accepted for poster presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place from April 17th – 22nd at San Diego Convention Center, San Diego, CA.

For additional information, please visit: https://bit.ly/4uqVJZ4

02/24/2026

: The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study in without modifications. Learn more: https://bit.ly/4aoDATy

02/19/2026

President and CEO Dr. William V. Williams shares insights into BriaCell and BriaPro’s asset purchase agreement for an exclusive soluble CD80 license. Learn more: https://bit.ly/3MxcYGY

02/18/2026

BriaCell (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXZL) (TSX: BCT) and BriaPro Therapeutics Corp. announced that they have entered into a definitive purchase agreement pursuant to which BriaPro has agreed to purchase BriaCell’s exclusive license to develop and commercialize Soluble CD80 as a biologic agent for the treatment of cancer and other associated assets. Find details: https://bit.ly/3MxcYGY

02/17/2026

BriaCell President and CEO Dr. William V. Williams commented on the fifth consecutive positive recommendation from Data Safety Monitoring Board (DSMB) for BriaCell's Phase 3 study in . Learn more: https://bit.ly/4aoDATy

02/17/2026

BriaCell (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXZL) (TSX: BCT) announced that the independent Data Safety Monitoring Board (DSMB) has issued its fifth consecutive positive recommendation following review of safety data from BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer. Find details: https://bit.ly/4aoDATy

Address

2929 Arch Street, 3rd Floor
Philadelphia, PA
19104

Telephone

+18884856340

Website

Alerts

Be the first to know and let us send you an email when BriaCell Therapeutics Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to BriaCell Therapeutics Corp.:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

BriaCell Therapeutics

Dedicated to enhance the lives of cancer patients who are facing limited therapeutic options, BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V)’s mission has been to develop novel immunotherapies, as the most cutting edge technology to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering higher levels of safety and efficacy than chemotherapy, with less likeliness of recurrence.

Designed by our team of scientists and clinicians, BriaCell’s proprietary whole-cell based technology platform continues to show its impressive potential to establish a new model for treating cancer patients. Our lead product candidate, Bria-IMT™ (SV-BR-1-GM), is a genetically engineered whole-cell based product candidate derived from a human breast cancer cell line. Bria-IMT™ is used in combination with multiple immune-modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells.